Literature DB >> 32839936

A Novel CREBBP in-Frame Deletion Variant in a Chinese Girl with Atypical Rubinstein-Taybi Syndrome Phenotypes.

Qingming Wang1,2, Wanfang Xu1, Yanhui Liu1,2, Haiming Yuan3,4.   

Abstract

Loss-of-function variants in CREBBP or EP300 result in Rubinstein-Taybi syndrome (RSTS). The previously reported cluster of variants in the last part of exon 30 and the beginning of exon 31 of CREBBP, overlapping with the ZNF2 (zinc finger, ZZ-type; residues 1701 to 1744) and ZNF3 (zinc finger, TAZ-type; residues 1764 to 1853) domains, is associated with atypical RSTS. The main features include developmental delay, short stature, microcephaly, distinctive facial features, autistic behavior, feeding difficulties, recurrent upper airway infections, and hearing impairment. Here, we report a 2-year-7-month-old Chinese girl presenting mild cognitive impairments, developmental delay, short stature, recurrent upper airway infections, and facial dysmorphism that resembled the phenotypes of previously reported atypical RSTS patients. The characteristic facial and limb dysmorphism for RSTS was absent in our patient. In addition, our patient exhibited novel phenotypes including attention deficit hyperactivity disorder (ADHD), sleep problem, and abnormal walking posture. Whole-exome sequencing (WES) identified a novel de novo in-frame deletion variant in the beginning of exon 30 of CREBBP (NM_004380:c.4897_4899delTTC, p.Phe1633del) in the HAT domain where no pathogenic variants have been previously reported to be responsible for atypical RSTS. Our case allows us to more accurately define the borders of the CREBBP coding sequence resulting in atypical RSTS, which are extended to the beginning of exon 30 (residue 1633) at the 5' end of CREBBP in the HAT domain, and reveals novel phenotypes observed in our atypical Chinese RSTS patient.

Entities:  

Keywords:  CREBBP; Exon 30; Exon 31; HAT domain; Rubinstein–Taybi syndrome

Year:  2020        PMID: 32839936     DOI: 10.1007/s12031-020-01681-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  17 in total

Review 1.  Rubinstein-Taybi syndrome.

Authors:  Raoul C M Hennekam
Journal:  Eur J Hum Genet       Date:  2006-07-26       Impact factor: 4.246

2.  Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.

Authors:  J P Lopez-Atalaya; C Gervasini; F Mottadelli; S Spena; M Piccione; G Scarano; A Selicorni; A Barco; L Larizza
Journal:  J Med Genet       Date:  2011-10-07       Impact factor: 6.318

3.  Genotype-phenotype specificity in Menke-Hennekam syndrome caused by missense variants in exon 30 or 31 of CREBBP.

Authors:  Siddharth Banka; Rebecca Sayer; Catherine Breen; Stephanie Barton; Julija Pavaine; Sarah E Sheppard; Emma Bedoukian; Cara Skraban; Vishnu A Cuddapah; Jill Clayton-Smith
Journal:  Am J Med Genet A       Date:  2019-03-20       Impact factor: 2.802

4.  Confirmation of a new phenotype in an individual with a variant in the last part of exon 30 of CREBBP.

Authors:  Andrea Angius; Paolo Uva; Manuela Oppo; Ivana Persico; Stefano Onano; Stefania Olla; Valentina Pes; Chiara Perria; Gianmauro Cuccuru; Rossano Atzeni; Gigliola Serra; Francesco Cucca; Stefano Sotgiu; Raoul C Hennekam; Laura Crisponi
Journal:  Am J Med Genet A       Date:  2019-02-08       Impact factor: 2.802

5.  Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.

Authors:  Leonie A Menke; Thatjana Gardeitchik; Peter Hammond; Ketil R Heimdal; Gunnar Houge; Sophia B Hufnagel; Jianling Ji; Stefan Johansson; Sarina G Kant; Esther Kinning; Eyby L Leon; Ruth Newbury-Ecob; Stefano Paolacci; Rolph Pfundt; Nicola K Ragge; Tuula Rinne; Claudia Ruivenkamp; Sulagna C Saitta; Yu Sun; Marco Tartaglia; Paulien A Terhal; Anthony J van Essen; Magnus D Vigeland; Bing Xiao; Raoul C Hennekam
Journal:  Am J Med Genet A       Date:  2018-02-20       Impact factor: 2.802

6.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.

Authors:  T Murata; R Kurokawa; A Krones; K Tatsumi; M Ishii; T Taki; M Masuno; H Ohashi; M Yanagisawa; M G Rosenfeld; C K Glass; Y Hayashi
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

7.  DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.

Authors:  Oliver Bartsch; Stefanie Schmidt; Marion Richter; Susanne Morlot; Eva Seemanová; Glenis Wiebe; Sasan Rasi
Journal:  Hum Genet       Date:  2005-07-14       Impact factor: 4.132

8.  Genetic basis of congenital upper limb anomalies: analysis of 487 cases of a specialized clinic.

Authors:  Diana Carli; Tracy Fairplay; Paola Ferrari; Silvana Sartini; Mario Lando; Lorenzo Garagnani; Giovanni Luigi Di Gennaro; Luciana Di Pancrazio; Giorgia Bianconi; Amira Elmakky; Sergio Bernasconi; Antonio Landi; Antonio Percesepe
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-12

9.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.

Authors:  F Petrij; R H Giles; H G Dauwerse; J J Saris; R C Hennekam; M Masuno; N Tommerup; G J van Ommen; R H Goodman; D J Peters
Journal:  Nature       Date:  1995-07-27       Impact factor: 49.962

10.  CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype.

Authors:  Leonie A Menke; Martine J van Belzen; Marielle Alders; Francesca Cristofoli; Nadja Ehmke; Patricia Fergelot; Alison Foster; Erica H Gerkes; Mariëtte J V Hoffer; Denise Horn; Sarina G Kant; Didier Lacombe; Eyby Leon; Saskia M Maas; Daniela Melis; Valentina Muto; Soo-Mi Park; Hilde Peeters; Dorien J M Peters; Rolph Pfundt; Conny M A van Ravenswaaij-Arts; Marco Tartaglia; Raoul C M Hennekam
Journal:  Am J Med Genet A       Date:  2016-06-17       Impact factor: 2.802

View more
  2 in total

1.  TTC5 syndrome: Clinical and molecular spectrum of a severe and recognizable condition.

Authors:  Luciana Musante; Flavio Faletra; Kolja Meier; Hoda Tomoum; Paria Najarzadeh Torbati; Edward Blair; Sally North; Jutta Gärtner; Susann Diegmann; Mehran Beiraghi Toosi; Farah Ashrafzadeh; Ehsan Ghayoor Karimiani; David Murphy; Flora Maria Murru; Caterina Zanus; Andrea Magnolato; Martina La Bianca; Agnese Feresin; Giorgia Girotto; Paolo Gasparini; Paola Costa; Marco Carrozzi
Journal:  Am J Med Genet A       Date:  2022-06-07       Impact factor: 2.578

2.  Bioinformatics Analysis of the Molecular Mechanism and Potential Treatment Target of Ankylosing Spondylitis.

Authors:  Fanyan Meng; Ningna Du; Daoming Xu; Li Kuai; Lanying Liu; Minning Xiu
Journal:  Comput Math Methods Med       Date:  2021-07-21       Impact factor: 2.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.